IHC4

Options
SelenaWolf
SelenaWolf Member Posts: 1,724
edited June 2014 in Canadians Affected by Breast Cancer

I've read (unfortunately, I cannot remember where, but I'm looking for the link), that - in Canada - one of the reasons the Oncotype DX, Mammoprint, and Mammostrat tests are not used to determine the course of adjuvent treatment is because they've found that the results are too uncertain- and/or risky for women who are under age 75 with ER+, HER2-, lymph node negative early breast cancers. 

Instead, the IHC4 test is being looked at as a more reliable indictor of whether- or not chemotherapy should be part of adjuvent treatment for the above.  Does anyone know anything about this?

· Share on FacebookShare on Twitter

Categories